Topical treatments to reduce severity of radiation dermatitis in breast cancer patients-a systematic review by Nakra, Tania & Ibrahim, Bunmi
*Correspondence to Author: 
Bunmi Ibrahim
School of Allied Health Sciences. 
De Montfort University, Leicester. 
United Kingdom.
How to cite this article:
Tania Nakra; Bunmi Ibrahim.Topical 
treatments to reduce severity of ra-
diation dermatitis in breast cancer 
patients-a systematic review.Amer-
ican Journal of Dermatological Re-
search and Reviews, 2021, 4:47.
eSciPub LLC, Houston, TX USA.
Website: https://escipub.com/
Tania Nakra et al., AJODRR, 2021, 4:47
 
American Journal of Dermatological Research and Reviews
(ISSN:2638-1893)
Review Article AJODRR (2021) 4:47
Topical treatments to reduce severity of radiation dermatitis in 
breast cancer patients-a systematic review
Breast cancer (BC) patients are likely to undergo radiotherapy 
(RT) treatment which may lead to the development of the skin 
toxicity, radiodermatitis (RD). The purpose of this systematic 
review is to evaluate the effectiveness of topical interventions 
in reducing the severity of RD in females BC patients. Appro-
priate clinical studies were independently identified through a 
bibliographic search in PubMed and clinicaltrials.gov. Nine ran-
domised, controlled clinical trials (RCTs) which stated a clear 
inclusion and exclusion criteria, were included in this review. 
The studies included in this review were conducted in the last 10 
years and researched the effectiveness of only topical therapies 
on female BC patients. The severity of RD starting at baseline 0 
to endpoint was measured using the Radiation Therapy Oncol-
ogy Group (RTOG) scale, and results show most patients expe-
rienced a RTOG score change of 0-1 or 0-2. A significant rela-
tionship between results obtained from 0-1 and 0-2 was shown 
(p < 0.00001). Results suggest Radioskin 1&2 cream is the most 
effective topical treatment for RD as 95% of patients experienced 
a RTOG score change of 0-1 compared to 5% experiencing 
0-2. However, controlled treatments like general care and Aqua 
Cream seem to be the least effective, as 1.9% of patients admin-
istrating general care experienced a RTOG score change of 0-1 
compared to 41.9% experiencing 0-2. 
Keywords: Breast cancer; Radiotherapy; Radiodermatitis; Topi-
cal Treatments 
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Introduction 
Breast cancer [BC] is the second most common 
cancer and the primary cause of death due to 
cancer in females worldwide, with over 2 million 
new BC cases in 2018 [1]. The diagnosis of BC 
involves mammography, Magnetic Resonance 
Imaging [MRI], Molecular Breast Imaging [MBI] 
and the most definitive method is breast biopsies 
[2]. Other investigation tests include 
immunohistochemistry to detect specific protein 
expression and blood-based assay using serum 
tumour breast biomarkers [CA 15-3, CEA and 
CA27-29] [2]. The treatments for BC comprise of 
surgical options including, lumpectomy, 
mastectomy or reconstruction, RT, systemic 
therapy involving chemo or hormonal therapy 
and target therapies [3]. However, the most 
popular approach in the management of BC is 
breast conservation surgery [BCS] followed by 
RT to minimise the risk of recurrence and ensure 
full recovery [2]. RT plays a vital role in managing 
BC and reducing recurrence rates, through 
destruction of subclinical diseases after surgical 
removal has taken place [4]. The benefits of RT 
should outweigh the potential side effects. 
Approximately, 45% of women diagnosed with 
BC receive RT and nearly all women experience 
some grade of RD, which is a very common side 
effect and therefore requires critical research [5].  
RD is a result of the rapid formation of free 
radicals after RT, within the basal layer and 
underlying dermis [6]. RT treatment causes 
changes including, a decrease in the level of 
functional stem cells, alteration of endothelial 
cells and elevating levels of several cytokines 
and chemokines like interleukin [IL]-1 which is 
responsible skin inflammation [6]. Patients 
suffering from RD experience a range of 
symptoms including oedema [swelling], moist 
desquamation [thinning of the skin], ulceration, 
itching, dry desquamation [severe dryness] 
erythema [severe redness] and pain or 
discomfort, which are assessed by physicians 
using standard grading systems [7]. The severity 
of the RD observed by physicians vary. 
Radiation Therapy Oncology Group [RTOG] or 
Common Terminology Criteria for Adverse 
Events [CTCAE’s] scales [Table 1] are the most 
common measures of the severity of RD and aid 
in the reproducible quantification of dermatitis [8]. 
Investigating the severity of RD using grading 
systems, provides useful information to generate 
effective treatment plans which may result in a 
better quality of life for the patient. Treatments 
for RD include topical corticosteroid creams, 
oral/topical antibiotics, or dressings [9].  
Various levels of efficacy have been reported in 
recent research [10]. A high-quality evaluation of 
the effectiveness of these treatments will help 
patients to make informed decisions and give 
health care professionals valid data to base 
counsel of the patients on. This review will 
therefore focus on the change of RTOG score 
from a baseline 0 to endpoint whilst using 
particular interventions. BC patients undergoing 
continuous RT for the first time will be analysed. 
The aim of the research is to assess the 
effectiveness of topical treatments of RD. The 
treatments including creams, moisturisers, gels 
or ointments in reducing the severity of RD.  
Materials and methods 
The electronic literature search included studies 
from the last 10 years. The search engines used 
to locate studies were PubMed and 
clinicaltrials.gov, however the presented trials 
after data extraction originated from PubMed. 
The search terms used were radiation 
dermatitis, topical treatment, and breast cancer. 
The Mesh descriptor for PubMed follows: 
[[radiation dermatitis] AND [topical treatment] 
AND [breast cancer]] and use of ‘last 10 years’ 
option on advanced search. A PRISMA flow 
chart shows the study selection process.  
RCTs assessing female BC patients who 
received no dosage of RT prior to the study were 
included. Eligible trials used only the RTOG 
scoring system to measure the change in the 
severity of RD. The intervention in each RCT 
must be compared to a control therapy or 
general care. The presented studies had internal 
quality through control of baseline 
characteristics and statistical analysis showing 
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significance of the outcomes. Excluded studies 
did not meet the inclusion criteria. Extracted 
experiments were not RCTs and alternatively 
designed as case reports, retrospective, or pilot 
studies. There was no restriction of patient 
characteristics including age, health status, or 
prior surgical treatment of BC. The inclusiveness 
of the definition of participants highlights the 
application of the results.  
 
Figure 1: PRISMA flow chart for identification of included and excluded studies 
 
Results 
In the nine studies included, the topical 
interventions assessed were: Vitamin D 
ointment, Aqua Cream, Topical Silver 
Sulfadiazine 1%, EGF-based cream, Betnovat & 
Essex, Essex and Canoderm, Boswellia cream, 
placebo cream, Neoviderm, Ixoderm, Radioskin 
1&2, Xderit, Trixera+, Leviaderm, Dexpanthenol 
5% and Calendula cream. In some studies, the 
treatment was compared to general care [11,12]. 
Pooling the results for the presented trials; the 
data consisted of 1195 participants. It was 
confirmed no participants had received any RT 
prior to the experiment, therefore baseline 
RTOG value is 0. However, the frequency of 
application of interventions differs between the 
trials. 
RTOG scores of all participants were 
documented [Table 1] after completion of RT. It 
shows that RTOG score changes 0-1 and 0-2 
are the most significant across the cohort. This 
outcome is supported by studies stating that 
most breast RD cases fall within range of Grades 
1 or 2 [8]. However, the highest percentage of 
patients [23.5%] who developed no sign of RD 
when undergoing RT was witnessed when 
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applying Leviaderm [13]. In contrast, it is shown 
that a combined treatment of Essex and 
Canoderm cream is the least effective as 4.1% 
of patients were observed with a RTOG score 
change of 0-4 [14]. Such severe change suggests 
very little effectiveness of the treatment. 
 
Table 1: The RTOG scores of all topical interventions including control from presented RCTs 
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Figure 2: A combination graph showing the comparison between the percentage of patients 
experiencing a RTOG score of 0-1 and 0-2 for each intervention 
 
The highest [95%] percentage of patients who 
experienced a toxicity grade change of 0-1 
observed was during administration of Radioskin 
1&2 cream [15] but, the controlled treatment of 
general care [11] resulted in the lowest 
percentage [1.9%] of patients with a 0-1 score 
change. In contrast the highest [74%] and lowest 
[5%] percentage of patients who experienced a 
RTOG score change of 0-2 was witnessed 
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during the application of Aqua Cream [16] and 
Radioskin 1&2 cream [15] respectively. 
Discussion 
RD is a major concern for patients suffering from 
BC and receiving RT treatment. Many RCTs 
[Table 2] have been carried out to show topical 
therapies which may be appropriate 
management techniques to improve care. This 
review is based solely on the effectiveness of 
topical treatments and does not consider the 
credibility of authors. Efforts have been made to 
quantify the degree of skin toxicity reactions 
using the RTOG scoring systems, which is an 
excellent quantifiable method used in trials 
researching RD severity [8]. Alternative valid 
scoring systems like the CTCAE scale have 
been used by other authors studying RD [17]. The 
outcome of the trial studying the efficacy of 
Bemethasone and a moisturizer as topical 
treatments for RD in BC patients, does not 
correlate with the findings of the presented trials. 
The most significant CTCAE score change was 
not 0-1 or 0-2, as majority of the patients 
remained with no RD whilst using Bemethasone 
[17]. Therefore, it was important to remain 
consistent with the scoring system for RD, to 
obtain accurate results. However, some authors 
use non-validated scales in published articles 
which were extracted from our data. It is 
necessary to combine the results of all RCT 
evaluating the effect of different topical therapies 
in a systematic review, to establish a distinct 
conclusion that could be used in medical 
practice.  
Combined results from the presented studies 
were documented in Table 1, showing that 
patients undergoing RT for the first time are most 
likely to receive RTOG score 1 or 2 at endpoint, 
however in a rare case Grade 4 was identified 
when applying a control treatment of Essex and 
Canoderm Cream [14]. 
There is a clear difference between the severity 
of each grade of the RTOG scores [18]. This 
confirms the need for effective topical treatment 
in medical practice to prevent patients from 
experiencing more severe and painful skin 
reactions as seen in RTOG score 3 or 4.  
The mechanism of RD involves an interaction 
between an inflammatory response caused by 
pro-inflammatory cytokines [IL-1, IL-3, IL-5, IL-6] 
or chemokines and oxidative stress [19]. This 
implies that effective treatments of RD should 
have antioxidative or anti-inflammatory 
properties. This is evident in topical 
corticosteroids, like Betamethasone, which 
blocks inflammation by targeting cytokines such 
as reducing the production of IL-1 and IL-2 [19]. 
Recent studies confirm a statistically significant 
reduction in RD severity when using the 
corticosteroid treatment of betamethasone [p < 
0.001] which are well-known inhibitors of skin 
inflammation [20]. Moreover, Table 1 shows that 
the highest percentage of patients experiencing 
a RTOG score change of 0-3 [52.9%] was 
observed when administrating controlled 
general care, which suggests this is an 
ineffective treatment of RD [11]. General care 
involves washing the area gently using mild baby 
soap [11]. As no anti-inflammatory agents or 
antioxidant are present, RD scores are more 
likely to worsen, which confirms the low efficacy 
of this treatment. Future trials should study the 
antioxidant and anti-inflammatory properties of 
interventions and state them clearly, in order to 
generate individually tailored treatment plans for 
patients. This is efficiently demonstrated in a 
RCT showing that a Boswellia-based cream is 
statistically significant in reducing the severity of 
RD [0.05 < p < 0.10]. This herbal, topical 
intervention contains Boswellic acids which are 
clearly described as having strong anti-
inflammatory properties [21].  
To determine effectiveness of topical therapies, 
combined analysis of the most significant 
results, RTOG scores 0-1 and 0-2, is required. 
Effective treatments should have a high 
percentage of patients experiencing a RTOG 
score change of 0-1, and a low percentage 
experiencing a RTOG score change of 0-2. This 
is shown when administrating Radioskin1&2 
cream or Neoviderm [15]. Figure 2 shows the 
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relationship between the results obtained and 
confirms the effectiveness of the studied 
interventions.    
Combined analysis shows that Radioskin 1&2 
cream is the most effective as 95% of patients 
experienced maximum toxicity change of 0-1, 
correlating to the low percentage [5%] of patients 
experiencing RTOG score change of 0-2. This 
intervention consists of a range of agents which 
make up both components of the treatment: Alga 
Atlantica, Ethylbisiminomethylguaicolo and 
Manganese Cloruro [Radioskin 1], Metal 
Esculetina, Ginko Biloba and Aloe vera 
[Radioskin 2] [15]. Therefore, the results may 
suggest a combination of treatments within one 
cream could have additional effects by 
decreasing the likelihood of experiencing severe 
RD. Further research into comparing the effect 
of combined topical therapy as a single 
treatment is necessary to further confirm this 
inference. Also, further evaluation of herbal 
contents of topical therapies, like aloe vera used 
in Radioskin 1&2 cream, is required. Herbal 
treatments may have specific mechanisms of 
action with high or low antioxidant materials, 
which could enhance or reduce treatment effects 
of RD. A previous study has shown aloe vera gel 
does not significantly reduce RD as a p value of 
0.06 was obtained [22]. Therefore, other herbal 
contents should be considered in combination 
treatments like Radioskin 1&2 cream, as this 
could enhance the positive effects of the 
medication. Studies have shown statistical 
significance [p=0.03] of Ayurvedic cream [based 
on sandalwood oil and turmeric] in reducing the 
degree of RD, as 15% of BC patients developed 
no signs of RD at endpoint [23].  
Statistical analysis confirms a significant 
negative correlation between the percentage of 
patients experiencing a RTOG score change of 




Figure 3: A regression model to show the relationship between RTOG score changes 0-1 and 0-2 
 
A p-value of 6.4 x 10-11 was determined 
therefore, the null hypothesis is rejected as there 
is a very statistically significant relationship 
between both results. As a result, it is evident 
that the values did not occur by chance, 
providing validity to the review and confirms the 
use of topical interventions in current medical 
practice. The determined R2 value [0.65] implies 
a good negative correlation between the two 
variables. Therefore, this suggests that 
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professionals conducting future research into 
this field can predict the outcome of their study. 
It would be possible to determine the expected 
percentage of patients experiencing a RTOG 
score change of 0-2 using the result of 0-1 or 
vice-versa. Therefore, this is an excellent 
method of providing credibility to future 
research. 
The outcome of this review suggests that 
moisturisers should be considered in medical 
practice, as the three most effective treatments 
determined are, Radioskin 1&2 cream, 
Neoviderm and Ixoderm [15]. These moisturisers 
were analysed in the same RCT using the one 
sample of 100 BC patients from Italy who had 
undergone BCS. Details are provided in Table 2. 
Conclusions can be easily drawn as each 
treatment group was similarly controlled and RD 
was measured in the same manner, using the 
RTOG scale. However, the sample was divided 
into 5 treatment groups and patients only applied 
the given intervention, therefore individual 
differences may impact the results. Hence, a 
repeated study using an alternative 
methodology, where each patient applied all 
treatments on specific areas of the breast [16], 
may be more effective as, there will be less 
influence of individual differences. Another 
limitation is that the sample is too small and 
specific as only 100 Italian BC patients were 
included, therefore it is not possible to generalise 
the findings globally. As shown in Table 2, aside 
from this study all presented trials were not 
carried out on large, multi-cultural cohorts. As 
this review only assessed RCTs from Europe or 
Asia it is difficult to apply the obtained results to 
worldwide populations. Even though the 
presented trials have internal validity, as the 
results are applicable to the tested sample, it 
may not be generalised beyond that group, 
which could be a possible limitation. This is 
important as research confirms that 
physiological properties of the skin like, 
hydration levels differ between races and, these 
implications alter the ability of different skin types 
to absorb topical therapeutic agents [24]. For 
instance, when measuring skin moisture or 
hydration, Black subjects had lower skin 
hydration compared to Caucasians [24]. 
Therefore, future trials should involve patients 
from all racial backgrounds to reduce the effect 
of extenuating factors. 
A previous systematic review studies the topical 
management of RD in BC patients [25]. There are 
limitations with this review as included studies 
used different tools in measuring RD, leading to 
differences in outcomes reported. Therefore, the 
current systematic review was designed to 
overcome this limitation and focus specifically on 
studies which used RTOG scoring scale, to 
minimise the effect of bias. Moreover, all patients 
began at a baseline of 0 and received no RT 
before the study began to ensure a clear RTOG 
score change can be observed. In contrast, a 
recent study evaluating the effectiveness of 
Epigallocatechin-3-gallate [EGCG] as a topical 
therapy for RD in breast cancer patients shows 
that 71.4% of patients with a baseline RTOG 
score of 1 remain at 1 once undergoing the 
treatment [26]. Therefore, this confirms that 
topical interventions are effective methods in 
preventing the severity of RD, however more 
research is required to ensure whether 
treatment is most effective when applied to 
patients with no RD or when patients develop 
Grade 1 dermatitis. There are limited studies 
available using the baseline RTOG value 1. 
In addition, the presented studies were not 
controlled for basic characteristics, including 
prior surgical treatment of BC, study duration 
and application of intervention [Table 2]. Some 
studies had a specific inclusion criterion, that 
only females who had undergone BCS [12,13,15,16] 
or radical mastectomy [RM] [11,27] were included. 
However, other presented studies did not control 
this factor, as BC patients either had BCS or 
modified RM [13,16,21]. This can be seen as an 
extenuating factor, as each female may 
experience different surgical effects which could 
interfere with the performance of the given 
intervention. The presented studies all provided 
a clear inclusion and exclusion criteria which is 
Tania Nakra et al., AJODRR, 2021,4:47 
AJODRR: https://escipub.com/american-journal-of-dermatological-research-and-reviews/           9
essential from high-quality research, in order to 
achieve a suitable sample. Also, Table 2 
indicates that most presented studies included 
baseline participant data to minimise the effect 
of extraneous variables like BMI, age, or 
brassiere cup size. As the baseline 
characteristics of each study populations were 
not controlled in this review, future studies 
should control this in order to minimise effects of 
other factors on the results. 
Moreover, further research into how topical 
interventions improve symptoms of RD 
including, moist desquamation and pain is 
essential.  Adverse of effect of RD can be 
assessed using Visual Analogue Scales [28]. A 
RCT investigated the number of days it took 
patients to develop a RTOG score of 2 and the 
occurrence of moist desquamation [29]. Results 
showed that the medicinal plant extract gel, 
Nigella Sativa L. 5%, significantly delayed 
incidence rate of RTOG Grade 2 and reduced 
the severity of moist desquamation [29]. 
Therefore, this supports the findings of this 
review and suggests further studies should 
consider comparing changes in symptoms 
alongside RD severity, to improve the quality of 
life of patients. 
Conclusion 
This review concluded that most topical 
interventions are effective in reducing the 
severity of RD. Therefore, this confirms the use 
of topical treatments in medical practice. The 
results indicate the most significant RTOG score 
changes observed were 0-1 and 0-2, and a good 
negative correlation is shown between the 
obtained values for both. In conclusion, the most 
effective intervention studied is Radioskin 1&2 
cream compared to general care as the least 
effective. Future studies should address adverse 
effects of RD including pain or moist 
desquamation and control administration of the 
agents as each patient should apply all studied 
treatments. 
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